ResMed (RMD) 10-Q 24 Jan 18 2018 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Dec. 31, 2017	Jan. 17, 2018
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2017
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q2
Trading Symbol	rmd
Entity Registrant Name	RESMED INC
Entity Central Index Key	943,819
Current Fiscal Year End Date	--06-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		142,927,127

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Current assets:
Cash and cash equivalents	$ 858,899	$ 821,935
Accounts receivable, net of allowance for doubtful accounts of $14,341 and $11,150 at December 31, 2017 and June 30, 2017, respectively	482,934	450,530
Inventories (note 2)	296,062	268,319
Prepaid expenses and other current assets	116,454	103,219
Total current assets	1,754,349	1,644,003
Non-current assets:
Property, plant and equipment, net (note 3)	401,537	394,241
Goodwill (note 4)	1,075,315	1,064,874
Other intangible assets, net (note 5)	240,027	261,800
Deferred income taxes	50,722	61,503
Other assets	42,050	42,066
Total non-current assets	1,809,651	1,824,484
Total assets	3,564,000	3,468,487
Current liabilities:
Accounts payable	78,351	92,763
Accrued expenses	189,368	186,295
Deferred revenue	53,284	51,918
Short-term income taxes payable (note 7)	16,276	29,150
Short-term debt, net (note 9)	1,019,132
Total current liabilities	1,356,411	360,126
Non-current liabilities:
Deferred revenue	63,289	53,235
Deferred income taxes	13,141	13,822
Other long-term liabilities	2,217	2,427
Long-term debt, net (note 9)		1,078,611
Long-term income taxes payable (note 7)	109,414
Total non-current liabilities	188,061	1,148,095
Total liabilities	1,544,472	1,508,221
Commitments and contingencies (note 13)
Stockholders’ equity: (note 10)
Preferred stock, $0.01 par value, 2,000,000 shares authorized; none issued
Common stock, $0.004 par value, 350,000,000 shares authorized; 184,078,205 issued and 142,891,971 outstanding at December 31, 2017 and 183,260,958 issued and 142,174,724 outstanding at June 30, 2017	572	569
Additional paid-in capital	1,409,993	1,379,130
Retained earnings	2,312,335	2,316,237
Treasury stock, at cost, 41,186,234 shares at December 31, 2017 and 41,086,234 shares at June 30, 2017	(1,555,152)	(1,546,611)
Accumulated other comprehensive loss	(148,220)	(189,059)
Total stockholders' equity	2,019,528	1,960,266
Total liabilities and stockholders' equity	$ 3,564,000	$ 3,468,487

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Condensed Consolidated Balance Sheets [Abstract]
Accounts receivable, net allowance for doubtful accounts	$ 14,341	$ 11,150
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued	0	0
Common stock, par value	$ 0.004	$ 0.004
Common stock, shares authorized	350,000,000	350,000,000
Common stock, shares issued	184,078,205	183,260,958
Common stock, shares outstanding	142,891,971	142,174,724
Treasury stock, shares held	41,186,234	41,086,234

Condensed Consolidated Statemen

Condensed Consolidated Statements Of Income - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Condensed Consolidated Statements Of Income [Abstract]
Net revenue	$ 601,273	$ 530,397	$ 1,124,932	$ 995,846
Cost of sales (excluding amortization of acquired intangible assets)	251,481	221,326	469,535	417,592
Gross profit	349,792	309,071	655,397	578,254
Operating expenses:
Selling, general and administrative	151,816	139,307	295,666	268,158
Research and development	40,643	38,190	78,058	72,637
Restructuring expenses		4,413		4,413
Litigation settlement expenses		8,500		8,500
Acquisition related expenses		10,076		10,076
Amortization of acquired intangible assets	11,317	11,690	23,099	23,431
Total operating expenses	203,776	212,176	396,823	387,215
Income from operations	146,016	96,895	258,574	191,039
Other income (loss), net:
Interest income	4,579	4,191	9,449	8,065
Interest expense	(7,370)	(6,628)	(15,155)	(12,994)
Other, net	(1,460)	1,749	(2,618)	3,021
Total other income (loss), net	(4,251)	(688)	(8,324)	(1,908)
Income before income taxes	141,765	96,207	250,250	189,131
Income taxes	132,238	19,464	154,599	36,282
Net income	$ 9,527	$ 76,743	$ 95,651	$ 152,849
Basic earnings per share (note 11)	$ 0.07	$ 0.54	$ 0.67	$ 1.08
Diluted earnings per share (note 11)	0.07	0.54	0.67	1.08
Dividend declared per share	$ 0.35	$ 0.33	$ 0.70	$ 0.66
Basic shares outstanding (000's)	142,715	141,310	142,511	141,048
Diluted shares outstanding (000's)	143,855	142,097	143,757	141,982

Condensed Consolidated Stateme5

Condensed Consolidated Statements Of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Condensed Consolidated Statements Of Comprehensive Income [Abstract]
Net income	$ 9,527	$ 76,743	$ 95,651	$ 152,849
Other comprehensive income (loss):
Foreign currency translation (loss) gain adjustments	4,450	(107,048)	40,839	(77,325)
Comprehensive income (loss)	$ 13,977	$ (30,305)	$ 136,490	$ 75,524

Condensed Consolidated Stateme6

Condensed Consolidated Statements Of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net income	$ 95,651	$ 152,849
Adjustment to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	58,945	55,504
Stock-based compensation costs	23,958	22,802
Impairment of cost-method investments	2,254	206
Changes in fair value of business combination contingent consideration		10,076
Changes in operating assets and liabilities, net of effect of acquisitions:
Accounts receivable	(26,145)	(7,080)
Inventories	(20,760)	(36,104)
Prepaid expenses, net deferred income taxes and other current assets	(2,858)	(15,197)
Accounts payable, accrued expenses and other	95,489	23,086
Net cash provided by operating activities	226,534	206,142
Cash flows from investing activities:
Purchases of property, plant and equipment	(32,000)	(29,247)
Patent registration costs	(4,624)	(4,603)
Business acquisitions, net of cash acquired		(3,184)
Investment in cost-method investments	(3,725)	(3,867)
Proceeds (payments) on maturity of foreign currency contracts	(3,330)	8,209
Net cash used in investing activities	(43,679)	(32,692)
Cash flows from financing activities:
Proceeds from issuance of common stock, net	6,587	9,816
Purchases of treasury stock	(8,541)
Proceeds from borrowings, net of borrowing costs	50,000	75,000
Repayment of borrowings	(110,000)	(80,000)
Dividend paid	(99,553)	(92,865)
Net cash used in financing activities	(161,507)	(88,049)
Effect of exchange rate changes on cash	15,616	(28,689)
Net increaase (decrease) in cash and cash equivalents	36,964	56,712
Cash and cash equivalents at beginning of period	821,935	731,434
Cash and cash equivalents at end of period	858,899	788,146
Supplemental disclosure of cash flow information:
Income taxes paid, net of refunds	51,456	60,282
Interest paid	15,155	13,098
Fair value of assets acquired, excluding cash		4,519
Liabilities assumed		(76)
Goodwill on acquisition		(2,095)
Deferred payments		836
Total cash component of purchase price		$ 3,184

Summary Of Significant Accounti

Summary Of Significant Accounting Policies	6 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Summary Of Significant Accounting Policies	(1) Summary of Significant Accounting Policies  Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2018 .  The condensed consolidated financial statements for the three and six months ended December 31, 2017 and December 31, 2016 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2017 .  Revenue Recognition  We generally record revenue on product sales at the time of shipment, which is when title transfers to the customer. We do not record revenue on product sales which require customer acceptance until we receive acceptance. We initially defer service revenue received in advance from service contracts and recognize that deferred revenue ratably over the life of the service contract. We initially defer revenue we receive in advance from rental unit contracts and recognize that deferred revenue ratably over the life of the rental contract. Otherwise, we recognize revenue from rental unit contracts ratably over the life of the rental contract. We include in revenue freight charges we bill to customers. We charge all freight-related expenses to cost of sales. Taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, are excluded from revenue.  We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. However, as part of our sales processes, we may provide upfront discounts for large orders, one-time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. We record the costs of all such programs as an adjustment to revenue at the time the related revenue is recognized. Our products are predominantly therapy-based equipment and require no installation. Therefore, we have no installation obligations. For multiple-element arrangements, we allocate arrangement consideration to the deliverables by use of the relative selling price method. The selling price used for each deliverable is based on vendor–specific objective evidence.  We also generate revenue from time-based licensing of our software and associated services. In most instances, revenue is generated under sales agreements with multiple elements comprising subscription fees and professional services, which typically have contract terms of one to three years. We evaluate each element in these multiple-element arrangements to determine whether they represent a separate unit of accounting and recognize each element as the services are performed.  Provision for Warranty  We provide for the estimated cost of product warranties at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.  New Accounting Pronouncements  (a) Recently issued accounting standards not yet adopted  ASU No. 2014-09, “Revenue from Contracts with Customers” In May, 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”), ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “new revenue recognition standards”) will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The guidance also requires improved disclosures on the nature, amount, timing, and uncertainty of revenue that is recognized.  We formed an implementation team in fiscal year June 30, 2017 to oversee adoption of the new revenue recognition standards. The implementation team completed the diagnostic phase of its project which has included assessing the composition and detailed review of our contract portfolio and selection of sample contracts for assessment. There are a number of steps in the team’s project plan that remain to be completed including: finalizing contract reviews, evaluating the impact, and working through required changes to systems, business processes and controls to support the adoption of the new revenue recognition standards. We expect there will be changes to our accounting policies to align with terminology and concepts in the new revenue recognition standards as well as increased disclosures relating to our revenue streams, contract-related balances and contract details.  The new revenue recognition standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2019 and early application is permitted for annual or interim periods beginning after December 15, 2016. The new guidance can be applied retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of the change recognized at the date of the initial application. Assuming the impact is not material, we expect to adopt the new revenue recognition standards using the modified retrospective method with an adjustment to beginning retained earnings for the cumulative effect of the change.  ASU No. 2016-01, "Financial Instruments - Overall" In January 2016, the FASB issued Accounting Standards Update ASU No. 2016-01, "Financial Instruments - Overall" (Topic 825-10). The amendments address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, and require equity securities to be measured at fair value with changes in fair value recognized through net income. The amendments also simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment for impairment quarterly at each reporting period. The amendments in ASU 2016-01 will be effective for our first quarter of the fiscal year ending June 30, 2019. An entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption, with prospective adoption of the amendments related to equity securities without readily determinable fair values existing as of the date of adoption. We are currently assessing the impact as this standard will be relevant for our Cost-Method Investments.  ASU No. 2016-02, “Leases” In February 2016, the FASB issued Accounting Standard Update ASU No. 2016-02, “Leases” (Topic 842). Under the new guidance , lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all leases, other than those that meet the definition of a short-term lease. This update will establish a lease asset and lease liability by lessees for those leases classified as operating under current GAAP. Leases will be classified as either operating or finance under the new guidance. Operating leases will result in straight-line expense in the income statement, similar to current operating leases, and finance leases will result in more expense being recognized in the earlier years of the lease term, similar to current capital leases. For lessors, the update will more closely align lease accounting to comparable guidance in the new revenue standards described.  The new standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2020 and early application is permitted. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the impact of this standard on our consolidated financial statements and expect to commence an implementation project during the fiscal year ending June 30, 2018. While the formal impact assessment has not commenced, we expect this amendment will affect the way we account for operating leases where we are the lessee (as described above), require reassessment of how we account for revenue where we are the lessor and will result in increased disclosures for all lease arrangements.  ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued Accounting Standard Update ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” (Topic 740). Under the new guidance, an entity is required to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs and eliminates the exception for an intra-entity transfer of an asset other than inventory. ASU 2016-16 will be effective for the first quarter of our fiscal year ending June 30, 2019 . If we enter into transactions within the scope of the standard, it could result in additional deferred tax balances being recognized at the time of the transfer.  (b) Recently adopted accounting pronouncements  We have not adopted any new accounting pronouncements during the six months ended December 31, 2017 .

Inventories

Inventories	6 Months Ended
	Dec. 31, 2017
Inventories [Abstract]
Inventories	(2) Inventories  Inventories were comprised of the following at December 31, 2017 and June 30, 2017 (in thousands):   December 31, 2017 June 30, 2017  Raw materials $ 79,246 $ 75,658  Work in progress 4,798 4,297  Finished goods 212,018 188,364  Total inventories $ 296,062 $ 268,319

Property, Plant And Equipment

Property, Plant And Equipment	6 Months Ended
	Dec. 31, 2017
Property, Plant And Equipment [Abstract]
Property, Plant And Equipment	(3) Property, Plant and Equipment  Property, plant and equipment were comprised of the following as of December 31, 2017 and June 30, 2017 (in thousands):   December 31, 2017 June 30, 2017  Machinery and equipment $ 243,738 $ 230,632  Computer equipment 161,199 154,032  Furniture and fixtures 51,429 47,074  Vehicles 7,963 7,667  Clinical, demonstration and rental equipment 93,386 86,024  Leasehold improvements 37,984 35,932  Land 55,859 55,311  Buildings 236,318 233,868  887,876 850,540  Accumulated depreciation and amortization (486,339) (456,299)  Property, plant and equipment, net $ 401,537 $ 394,241

Goodwill

Goodwill	6 Months Ended
	Dec. 31, 2017
Goodwill And Other Intangible Assets [Abstract]
Goodwill	(4) Goodwill Changes in the carrying amount of goodwill for six months ended December 31, 2017 , and December 31, 2016 , were as follows (in thousands):   Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ 1,064,874 $ 1,059,245  Business acquisition - (2,095)  Foreign currency translation adjustments 10,441 (10,846)  Balance at the end of the period $ 1,075,315 $ 1,046,304

Other Intangible Assets

Other Intangible Assets	6 Months Ended
	Dec. 31, 2017
Goodwill And Other Intangible Assets [Abstract]
Other Intangible Assets	(5) Other Intangible Assets Other intangible assets were comprised of the following as of December 31, 2017 and June 30, 2017 (in thousands):    December 31, 2017 June 30, 2017  Developed/core product technology $ 208,445 $ 206,258  Accumulated amortization (108,715) (93,079)  Developed/core product technology, net 99,730 113,179  Trade names 48,880 48,768  Accumulated amortization (13,976) (10,894)  Trade names, net 34,904 37,874  Non-compete agreements 3,688 3,660  Accumulated amortization (2,490) (2,236)  Non-compete agreements, net 1,198 1,424  Customer relationships 123,957 122,458  Accumulated amortization (47,465) (40,050)  Customer relationships, net 76,492 82,408  In-process research and development 4,100 4,100  Accumulated amortization - -  In-process research and development, net 4,100 4,100  Patents 92,116 85,780  Accumulated amortization (68,513) (62,965)  Patents, net 23,603 22,815  Total other intangibles, net $ 240,027 $ 261,800  Intangible assets consist of developed/core product technology, trade names, non-compete agreements, customer relationships, and patents, which we amortize over the estimated useful life of the assets, generally between two and fifteen years. There are no expected residual values related to these intangible assets. In-process research and development is amortized over the estimated useful life of the assets, once the research and development efforts are completed. At least on an annual basis, we evaluate the in-process research and development balances for impairment.

Cost-Method Investments

Cost-Method Investments	6 Months Ended
	Dec. 31, 2017
Cost-Method Investments [Abstract]
Cost-Method Investments	(6) Cost-Method Investments  The aggregate carrying amount of our cost-method investments at December 31, 2017 and June 30, 2017 , was $39.8 million and $38.3 million, respectively, and is included in the non-current balance of other assets on the condensed consolidated balance sheets.  We periodically evaluate the carrying value of our cost-method investments, when events and circumstances indicate that the carrying amount of an asset may not be recovered. We estimate the fair value of our cost-method investments to assess whether impairment losses shall be recorded using Level 3 inputs. These investments include our holdings in privately held service and research companies that are not exchange traded and therefore not supported with observable market prices. However, these investments are valued by reference to their net asset values that can be market supported and unobservable inputs including future cash flows. During the six months ended December 31, 2017 and 2016 , we recognized $2.3 million and $0.2 million, respectively, of impairment losses related to our cost-method investments. We have determined, after the impairment charge, that the fair value of our remaining investments exceed their carrying values.  The following table shows a reconciliation of the changes in our cost-method investments during the six months ended December 31, 2017 and December 31, 2016 (in thousands):   Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ 38,324 $ 33,815  Investments 3,725 3,867  Impairment of cost-method investments (2,254) (206)  Balance at the end of the period $ 39,795 $ 37,476

Income Taxes

Income Taxes	6 Months Ended
	Dec. 31, 2017
Income Taxes [Abstract]
Income Taxes	(7) Income Taxes  In accordance with ASC 740 Income Taxes , each interim reporting period is considered integral to the annual period, and tax expense is measured using an estimated annual effective tax rate. An entity is required to record income tax expense each quarter based on its annual effective tax rate estimated for the full fiscal year and use that rate to provide for income taxes on a current year-to-date basis, adjusted for discrete taxable events that occur during the interim period.  Our income tax returns are based on calculations and assumptions subject to audit by various tax authorities. In addition, the calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws. We regularly assess the potential outcomes of examinations by tax authorities in determining the adequacy of our provision for income taxes. Any final assessment resulting from tax audits may result in material changes to our past or future taxable income, tax payable or deferred tax assets, and may require us to pay penalties and interest that could materially adversely affect our financial results .  We are currently under audit by the Australian Taxation Office (“ATO”) for the tax years 2009 to 2013 . In December 2017, we received a Statement of Audit Position from the ATO which provides the ATO auditor’s position on the factual and technical issues under audit, and included proposed adjustments totaling approximately $150.0 million in additional tax. The audit is ongoi ng and we have not received a Notice of Amended Assessment. We do not agree with the ATO’s position and continue to believe we are more likely than not to be successful in defending our position, and therefore have not recognized any additional tax liabilities in relation to this audit. We will pursue all administrative and legal steps in defense of our position; however, if we are not successful in defending our position, the outcome may materially adversely affect our financial results.  Our income tax expense, short-term income taxes payable and long-term income taxes payable were impacted by charges associated with the Tax Cuts and Jobs Act (“U.S. legislation”) enacted on December 22, 2017, which resulted in additional income tax expense of $126.6 million. Specifically, the income tax expense includes both the transition tax imposed on our accumulated foreign earnings, which resulted in additional income tax expense of $119.9 million, and the write down in the carrying value of our net deferred tax assets due to the lower corporate tax rate, which resulted in additional income tax expense of $6.7 million.  On December 22, 2 0 1 7, the SEC issued guidance under Staff Accounting Bulletin No. 118, Income Tax Accounting Implications of the Tax Cuts and Jobs Act (“SAB 118”) directing taxpayers to consider the impact of the U.S. legislation as “provisional” when it does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the change in tax law. In accordance with SAB 118, the additional estimated income tax of $126.6 million represents our best estimate based on interpretation of the U.S. legislation as we are still accumulating data to finalize the underlying calc ulations, or in certain cases, the U.S. Treasury is expected to issue further guidance on the application of certain provisio ns of the U.S. legislation. In accordance with SAB 118, the additional estimated income tax of $126.6 million is considered provisional and will be finalize d before December 22, 2018.

Product Warranties

Product Warranties	6 Months Ended
	Dec. 31, 2017
Product Warranties [Abstract]
Product Warranties	(8) Product Warranties  Changes in the liability for warranty costs, which is included in accrued expenses in our condensed consolidated balance sheets, for the six months ended December 31, 2017 and December 31, 2016 , are as follows (in thousands):    Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ 19,558 $ 15,043  Warranty accruals for the period 8,375 8,851  Warranty costs incurred for the period (7,493) (6,125)  Foreign currency translation adjustments 423 (855)  Balance at the end of the period $ 20,863 $ 16,914

Debt

Debt	6 Months Ended
	Dec. 31, 2017
Debt [Abstract]
Debt	(9) Debt Debt at December 31, 2017 and June 30, 2017 consisted of the following (in thousands):   December 31, 2017 June 30, 2017  Short-term debt $ 1,020,000 $ -  Deferred borrowing costs (868) -  Short-term debt, net 1,019,132 -  -  Long-term debt $ - $ 1,080,000  Deferred borrowing costs - (1,389)  Long-term debt, net $ - $ 1,078,611  Total debt $ 1,019,132 $ 1,078,611  Credit Facility  On October 31, 2013, we entered into a revolving credit agreement, as borrower, with lenders, including Union Bank, N.A., as administrative agent, joint lead arranger, swing line lender and letters of credit issuer, and HSBC Bank USA, National Association, as syndication agent and joint lead arranger, providing for a revolving credit facility of $700 .0 million, with an uncommitted option to increase the revolving credit facility by an additional $300 .0 million. On April 4, 2016, in connection with our acquisition of Brightree LLC (“Brightree”), we entered into a first amendment to the revolving credit agreement to increase the size of the revolving credit facility from $700 .0 million to $1 .0 billion, with an uncommitted option to increase the revolving credit facility by an additional $300 .0 million, and to make other modifications to provide for the acquisition of Brightree. On January 9, 2017, we entered into a second amendment to our agreement with our existing lenders, including MUFG Union Bank, N.A. as successor in interest to Union Bank, N.A., as Administrative Agent, Joint Lead Arranger, Swing Line Lender and L/C Issuer; and HSBC Bank USA, National Association, as Syndication Agent and Joint Lead Arranger. The second amendment, among other things, increased the size of our senior unsecured revolving credit facility from $1.0 billion to $1.3 billion, with an uncommitted option to increase the revolving credit facility by an additional $300 .0 million. The credit facility terminates on October 31, 2018 , when all unpaid principal and interest under the loans must be repaid. The outstanding principal amount due under the credit facility bears interest at a rate equal to LIBOR plus 1.0% to 2.0% (depending on the then-applicable leverage ratio). At December 31, 2017 , the interest rate that was being charged on the outstanding principal amount was 2.8% . A commitment fee of 0.15% to 0.25% (depending on the then-applicable leverage ratio) applies on the unused portion of the credit facility. The credit facility also includes a $25 .0 million sublimit for letters of credit.  Our obligations under the revolving credit agreement are unsecured but are guaranteed by certain of our direct and indirect U. S. subsidiaries, including ResMed Corp., ResMed Motor Technologies Inc., Birdie Inc., Inova Labs, Inc., Brightree, Brightree Services LLC, Brightree Home Health & Hospice LLC and Strategic AR LLC, under an unconditional guaranty. The credit agreement contains customary covenants, including certain financial covenants and an obligation that we maintain certain financial ratios, including a maximum leverage ratio of funded debt to EBITDA (as defined in the credit agreement) and an interest coverage ratio.  At December 31, 2017 , there was $1,020.0 million outstanding under the revolving credit facility.

Stockholders' Equity

Stockholders' Equity	6 Months Ended
	Dec. 31, 2017
Stockholders' Equity [Abstract]
Stockholders' Equity	(10) Stockholders’ Equity  Common Stock. During the six months ended December 31, 2017 , we repurchased 100,000 shares at a cost of $8.5 million. Since the inception of our share repurchase programs and through December 31, 2017 , we have repurchased a total of 41.2 million shares at a cost of $1.5 billion. Shares that are repurchased are classified as treasury stock pending future use and reduce the number of shares outstanding used in calculating earnings per share. There is no expiration date for this program, and the program may be accelerated, suspended, delayed or discontinued at any time at the discretion of our board of directors. At December 31, 2017 , 13.5 million additional shares can be repurchased under the approved share repurchase program.  Preferred Stock. In April 1997, the board of directors designated 2.0 million shares of our $0.01 par value preferred stock as Series A Junior Participating Preferred Stock. No shares were issued or outstanding at December 31, 2017 and June 30, 2017 .  Stock Options and Restricted Stock Units. We have granted stock options and restricted stock units to personnel, including officers and directors, in accordance with the amended and restated ResMed Inc. 2009 Incentive Award Plan ( as amended and restated the “2009 Plan”). The options have expiration dates of seven years from the date of grant and the options and restricted stock units vest over one to four years.  At the annual meeting of our stockholders in November 2017, our stockholders approved an amendment and restatement to the 2009 Plan to increase the number of shares of common stock that may be issued or transferred pursuant to awards under the 2009 Plan by 7.4 million. While these additional shares have been authorized by the stockholders, they are pending registration with the SEC.  The amendment and restatement imposed a maximum award amount which may be granted under the 2009 Plan to non-employee director in a calendar year, which when taken together with any other cash fees earned for services as a non-employee director during the calendar year, has a total value of $0.7 million, or $1.2 million in the case of a non-employee director who is also serving as chairman of our board of directors. The amendment and restatement also increased the maximum amount payable pursuant to cash-denominated performance awards granted to any US Internal Revenue Code Section 162(m) “covered employee” in any calendar year from $3.0 million to $5.0 million. In addition, the amendment and restatement extended the existing prohibition on the payment of dividends or dividend equivalents on unvested awards to apply to all awards, including time-based restricted stock, deferred stock and stock payment. The term of the 2009 Plan was extended by four years so that the plan expires on September 11, 2027 . The amendment became effective on the date of adoption by our board of directors which was September 11, 2017 .  At December 31, 2017 , t he maximum number of shares of our common stock authorized for issuance under the 2009 Plan is 51.1 million shares. The number of securities remaining available for future issuance under the 2009 Plan at December 31, 2017 is 17.6 million. The following table summarizes option activity during the six months ended December 31, 2017 :   Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,495,573 $ 47.09 3.9  Granted 238,815 84.98  Exercised (362,522) 33.34  Forfeited - -  Outstanding at end of period 1,371,866 $ 57.32 4.5  Exercise price of granted options $ 84.98  Options exercisable at end of period 849,755 $ 49.14  The following table summarizes the activity of restricted stock units during the six months ended December 31, 2017 :   Restricted Stock Units Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,906,394 $ 53.26 1.6  Granted 472,155 80.07  Vested (624,617) 52.05  Expired (8,415) 53.25  Forfeited (13,023) 53.25  Outstanding at end of period 1,732,494 $ 62.53 2.1  Employee Stock Purchase Plan (the “ESPP”). Under the ESPP, we offer participants the right to purchase shares of our common stock at a discount during successive offering periods. During the six months ended December 31, 2017 and December 31, 2016 , we issued 148,000 and 142,000 shares to our employees associated with the ESPP, respectively. At December 31, 2017 , the number of shares remaining available for future issuance under the ESPP is 0.7 million shares .

Earnings Per Share

Earnings Per Share	6 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Earnings Per Share	(11) Earnings Per Share  Basic earnings per share is computed by dividing the net income available to common stockholders by the weighted average number of shares of common stock outstanding. For purposes of calculating diluted earnings per share, the denominator includes both the weighted average number of shares of common stock outstanding and the number of dilutive common stock equivalents such as stock options and restricted stock units.  Stock options and restricted stock units of 126,390 and 410,520 for the three months ended December 31, 2017 and December 31, 2016 , respectively, and stock options and restricted stock units of 159,603 and 337,487 for the six months ended December 31, 2017 and December 31, 2016 , respectively, were not included in the computation of diluted earnings per share as the effect would have been anti-dilutive.  Basic and diluted earnings per share for the three and six months ended December 31, 2017 and December 31, 2016 are calculated as follows (in thousands except per share data):   Three Months Ended December 31, Six Months Ended December 31,  2017 2016 2017 2016  Numerator:  Net income $ 9,527 $ 76,743 $ 95,651 $ 152,849  Denominator:  Basic weighted-average common shares outstanding 142,715 141,310 142,511 141,048  Effect of dilutive securities:  Stock options and restricted stock units 1,140 787 1,246 934  Diluted weighted average shares 143,855 142,097 143,757 141,982  Basic earnings per share $ 0.07 $ 0.54 $ 0.67 $ 1.08  Diluted earnings per share $ 0.07 $ 0.54 $ 0.67 $ 1.08

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Dec. 31, 2017
Fair Value Measurements [Abstract]
Fair Value Measurements	(12) Fair Value Measurements  In determining the fair value measurements of our financial assets and liabilities, we consider the principal and most advantageous market in which we transact and consider assumptions that market participants would use when pricing the financial asset or liability. We maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value.  The hierarchies of inputs are as follows:     Level 1: Input prices quoted in an active market for identical financial assets or liabilities;   Level 2: Inputs other than prices quoted in Level 1, such as prices quoted for similar financial assets and liabilities in active markets, prices for identical assets and liabilities in markets that are not active or other inputs that are observable or can be corroborated by observable market data; and   Level 3 Input prices quoted that are significant to the fair value of the financial assets or liabilities which are not observable nor supported by an active market.  The following table summarizes our financial assets and liabilities, at December 31, 2017 and June 30, 2017 , using the valuation input hierarchy (in thousands):    Level 1 Level 2 Level 3 Total  Balances at December 31, 2017  Foreign currency hedging instruments, net $ - $ 7,669 $ - $ 7,669  Business acquisition contingent consideration $ - $ - $ (1,580) $ (1,580)  Balances at June 30, 2017  Foreign currency hedging instruments, net $ - $ 2,760 $ - $ 2,760  Business acquisition contingent consideration $ - $ - $ (1,580) $ (1,580)  We determine the fair value of our financial assets and liabilities as follows:  Foreign currency hedging instruments – These financial instruments are valued using third-party valuation models based on market observable inputs, including interest rate curves, on-market spot currency prices, volatilities and credit risk.  Contingent consideration – These liabilities include the fair value estimates of additional future payments that may be required for some of our previous business acquisitions based on the achievement of certain performance milestones. Each potential future payment is valued using the estimated probability of achieving each milestone, which is then discounted to present value.  The following is a reconciliation of changes in the fair value of contingent consideration for the six months ended December 31, 2017 and December 31, 2016 (in thousands):    Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ (1,580) $ (10,450)  Changes in fair value included in operating income - (10,076)  Foreign currency translation adjustments - 19  Balance at the end of the period $ (1,580) $ (20,507)  We did not have any significant non-financial assets or liabilities measured at fair value on December 31, 2017 or June 30, 2017 .

Legal Actions And Contingencies

Legal Actions And Contingencies	6 Months Ended
	Dec. 31, 2017
Legal Actions And Contingencies [Abstract]
Legal Actions And Contingencies	(13) Legal Actions and Contingencies  Litigation In the normal course of business, we are subject to routine litigation incidental to our business. While the results of this litigation cannot be predicted with certainty, we believe that their final outcome will not, individually or in aggregate, have a material adverse effect on our consolidated financial statements taken as a whole.  Contingent Obligations Under Recourse Provisions  We use independent leasing companies to offer financing to some of our customers for the purchase of some of our products. Under these arrangements, if the customer qualifies under the leasing company’s credit criteria and finances the transaction, the customers repay the leasing company on a fixed payment plan. For some of these arrangements, the customer’s receivable balance is with recourse, either limited or full, whereby we are responsible for repaying the leasing company should the customer default. We record the outstanding amount of receivables with full recourse in accrued expenses, which is offset by an equivalent amount recorded in accounts receivable. Additionally, we record a contingent provision for doubtful accounts for expected customer defaults based on historical default rates and any specific customer accounts with collection issues.  The following table summarizes the amount of receivables sold with recourse during the six months ended December 31, 2017 and December 31, 2016 (in thousands):     Six Months Ended December 31,  2017 2016  Total receivables sold:  Full recourse $ 9,882 $ 8,455  Limited recourse 35,960 33,794  Total 45,842 42,249  The following table summarizes the maximum exposure on outstanding receivables sold with recourse and provision for doubtful accounts at December 31, 2017 and June 30, 2017 ( in thousands) :     December 31, 2017 June 30, 2017  Maximum exposure on outstanding receivables:  Full recourse $ 18,312 $ 18,068  Limited recourse 8,687 9,432  Total 26,999 27,500   Provision for doubtful accounts - recourse receivables $ (1,279) $ (1,437)

Derivative Instruments And Hedg

Derivative Instruments And Hedging Activities	6 Months Ended
	Dec. 31, 2017
Derivative Instruments And Hedging Activities [Abstract]
Derivative Instruments And Hedging Activities	(14) Derivative Instruments and Hedging Activities  We transact business in various foreign currencies, including a number of major European currencies as well as the Australian and Singapore dollars. We have significant foreign currency exposure through both our Australian and Singapore manufacturing activities, and international sales operations. We have established a foreign currency hedging program using purchased currency options and forward contracts to hedge foreign-currency-denominated financial assets, liabilities and manufacturing cash flows. The terms of such foreign currency hedging contracts generally do not exceed three years. The goal of this hedging program is to economically manage the financial impact of foreign currency exposures denominated mainly in Euros, and Australian and Singapore dollars. Under this program, increases or decreases in our foreign currency denominated financial assets, liabilities, and firm commitments are partially offset by gains and losses on the hedging instruments. We do not designate these foreign currency contracts as hedges. We have determined our hedge program to be a non-effective hedge as defined under the FASB issued authoritative guidance. All movements in the fair value of the foreign currency instruments are recorded within other income, net in our condensed consolidated statements of income. We do not enter into financial instruments for trading or speculative purposes.  We held foreign currency instruments with notional amounts totaling $789.3 million and $ 568.2 million at December 31, 2017 and June 30, 2017 , respectively, to hedge foreign currency fluctuations. These contracts mature at various dates prior to December 31, 20 19 .  The following table summarizes the amount and location of our derivative financial instruments as of December 31, 2017 and June 30, 2017 (in thousands):   December 31, 2017 June 30, 2017 Balance Sheet Caption  Foreign currency hedging instruments $ 9,687 $ 2,614 Other assets - current  Foreign currency hedging instruments (126) 1,273 Other assets - non current  Foreign currency hedging instruments (1,892) (1,127) Accrued expenses  $ 7,669 $ 2,760  The following table summarizes the amount and location of gains (losses) associated with our derivative financial instruments for the six months ended December 31, 2017 and December 31, 2016 , respectively (in thousands):   Gain /(Loss) Recognized Income Statement Caption  Six Months Ended December 31,  2017 2016  Foreign currency hedging instruments $ 1,570 $ (18,713) Other, net  Other foreign-currency-denominated transactions (2,379) 21,695 Other, net  $ (809) $ 2,982  We are exposed to credit-related losses in the event of non-performance by counter parties to financial instruments. We minimize counterparty credit risk by entering into derivative transactions with major financial institutions and we do not expect material losses as a result of default by our counterparties.

Summary Of Significant Accoun21

Summary Of Significant Accounting Policies (Policy)	6 Months Ended
	Dec. 31, 2017
Summary Of Significant Accounting Policies [Abstract]
Organization And Basis Of Presentation	Organization and Basis of Presentation  ResMed Inc. (referred to herein as “we”, “us”, “our” or the “Company”) is a Delaware corporation formed in March 1994 as a holding company for the ResMed Group. Through our subsidiaries, we design, manufacture and market equipment for the diagnosis and treatment of sleep-disordered breathing and other respiratory disorders, including obstructive sleep apnea. Our manufacturing operations are located in Australia, Singapore, Malaysia, France, China and the United States. Major distribution and sales sites are located in the United States, Germany, France, the United Kingdom, Switzerland, Australia, Japan, China, Norway and Sweden.  The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and the rules of the U.S. Securities and Exchange Commission (“SEC”). Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. In the opinion of management, all necessary adjustments, which consisted only of normal recurring items, have been included in the accompanying financial statements to present fairly the results of the interim periods. The results of operations for the interim periods presented are not necessarily indicative of the results that may be expected for the year ending June 30, 2018 .  The condensed consolidated financial statements for the three and six months ended December 31, 2017 and December 31, 2016 are unaudited and should be read in conjunction with the consolidated financial statements and notes thereto included in our Form 10-K for the year ended June 30, 2017 .
Revenue Recognition	Revenue Recognition  We generally record revenue on product sales at the time of shipment, which is when title transfers to the customer. We do not record revenue on product sales which require customer acceptance until we receive acceptance. We initially defer service revenue received in advance from service contracts and recognize that deferred revenue ratably over the life of the service contract. We initially defer revenue we receive in advance from rental unit contracts and recognize that deferred revenue ratably over the life of the rental contract. Otherwise, we recognize revenue from rental unit contracts ratably over the life of the rental contract. We include in revenue freight charges we bill to customers. We charge all freight-related expenses to cost of sales. Taxes assessed by government authorities that are imposed on and concurrent with revenue-producing transactions, such as sales and value added taxes, are excluded from revenue.  We do not recognize revenues to the extent that we offer a right of return or other recourse with respect to the sale of our products, other than returns for product defects or other warranty claims, nor do we recognize revenues if we offer variable sale prices for subsequent events or activities. However, as part of our sales processes, we may provide upfront discounts for large orders, one-time special pricing to support new product introductions, sales rebates for centralized purchasing entities or price-breaks for regular order volumes. We record the costs of all such programs as an adjustment to revenue at the time the related revenue is recognized. Our products are predominantly therapy-based equipment and require no installation. Therefore, we have no installation obligations. For multiple-element arrangements, we allocate arrangement consideration to the deliverables by use of the relative selling price method. The selling price used for each deliverable is based on vendor–specific objective evidence.  We also generate revenue from time-based licensing of our software and associated services. In most instances, revenue is generated under sales agreements with multiple elements comprising subscription fees and professional services, which typically have contract terms of one to three years. We evaluate each element in these multiple-element arrangements to determine whether they represent a separate unit of accounting and recognize each element as the services are performed.
Provision For Warranty	Provision for Warranty  We provide for the estimated cost of product warranties at the time the related revenue is recognized. We determine the amount of this provision by using a financial model, which takes into consideration actual historical expenses and potential risks associated with our different products. We use this financial model to calculate the future probable expenses related to warranty and the required level of the warranty provision. Although we engage in product improvement programs and processes, our warranty obligation is affected by product failure rates and costs incurred to correct those product failures. Should actual product failure rates or estimated costs to repair those product failures differ from our estimates, we would be required to revise our estimated warranty provision.
New Accounting Pronouncements	New Accounting Pronouncements  (a) Recently issued accounting standards not yet adopted  ASU No. 2014-09, “Revenue from Contracts with Customers” In May, 2014, the Financial Accounting Standards Board (the “FASB”) issued Accounting Standards Update (“ASU”), ASU No. 2014-09, “Revenue from Contracts with Customers” (Topic 606), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. Since its initial release, the FASB has issued several amendments to the standard, which include clarification of accounting guidance related to identification of performance obligations, intellectual property licenses, and principal vs. agent considerations. ASU 2014-09 and all subsequent amendments (collectively, the “new revenue recognition standards”) will replace most existing revenue recognition guidance in U.S. GAAP when it becomes effective. The guidance also requires improved disclosures on the nature, amount, timing, and uncertainty of revenue that is recognized.  We formed an implementation team in fiscal year June 30, 2017 to oversee adoption of the new revenue recognition standards. The implementation team completed the diagnostic phase of its project which has included assessing the composition and detailed review of our contract portfolio and selection of sample contracts for assessment. There are a number of steps in the team’s project plan that remain to be completed including: finalizing contract reviews, evaluating the impact, and working through required changes to systems, business processes and controls to support the adoption of the new revenue recognition standards. We expect there will be changes to our accounting policies to align with terminology and concepts in the new revenue recognition standards as well as increased disclosures relating to our revenue streams, contract-related balances and contract details.  The new revenue recognition standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2019 and early application is permitted for annual or interim periods beginning after December 15, 2016. The new guidance can be applied retrospectively to each prior reporting period presented, or retrospectively with the cumulative effect of the change recognized at the date of the initial application. Assuming the impact is not material, we expect to adopt the new revenue recognition standards using the modified retrospective method with an adjustment to beginning retained earnings for the cumulative effect of the change.  ASU No. 2016-01, "Financial Instruments - Overall" In January 2016, the FASB issued Accounting Standards Update ASU No. 2016-01, "Financial Instruments - Overall" (Topic 825-10). The amendments address certain aspects of recognition, measurement, presentation, and disclosure of financial instruments, and require equity securities to be measured at fair value with changes in fair value recognized through net income. The amendments also simplify the impairment assessment of equity investments without readily determinable fair values by requiring a qualitative assessment for impairment quarterly at each reporting period. The amendments in ASU 2016-01 will be effective for our first quarter of the fiscal year ending June 30, 2019. An entity should apply the amendments by means of a cumulative-effect adjustment to the balance sheet as of the beginning of the fiscal year of adoption, with prospective adoption of the amendments related to equity securities without readily determinable fair values existing as of the date of adoption. We are currently assessing the impact as this standard will be relevant for our Cost-Method Investments.  ASU No. 2016-02, “Leases” In February 2016, the FASB issued Accounting Standard Update ASU No. 2016-02, “Leases” (Topic 842). Under the new guidance , lessees are required to recognize a right-of-use asset and a lease liability on the balance sheet for all leases, other than those that meet the definition of a short-term lease. This update will establish a lease asset and lease liability by lessees for those leases classified as operating under current GAAP. Leases will be classified as either operating or finance under the new guidance. Operating leases will result in straight-line expense in the income statement, similar to current operating leases, and finance leases will result in more expense being recognized in the earlier years of the lease term, similar to current capital leases. For lessors, the update will more closely align lease accounting to comparable guidance in the new revenue standards described.  The new standard is effective for us beginning in the first quarter of the fiscal year ending June 30, 2020 and early application is permitted. ASU 2016-02 will be adopted on a modified retrospective transition basis for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. We are currently evaluating the impact of this standard on our consolidated financial statements and expect to commence an implementation project during the fiscal year ending June 30, 2018. While the formal impact assessment has not commenced, we expect this amendment will affect the way we account for operating leases where we are the lessee (as described above), require reassessment of how we account for revenue where we are the lessor and will result in increased disclosures for all lease arrangements.  ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” In October 2016, the FASB issued Accounting Standard Update ASU No. 2016-16, “Income Taxes: Intra-Entity Transfers of Assets Other Than Inventory” (Topic 740). Under the new guidance, an entity is required to recognize the income tax consequences of an intra-entity transfer of an asset other than inventory when the transfer occurs and eliminates the exception for an intra-entity transfer of an asset other than inventory. ASU 2016-16 will be effective for the first quarter of our fiscal year ending June 30, 2019 . If we enter into transactions within the scope of the standard, it could result in additional deferred tax balances being recognized at the time of the transfer.  (b) Recently adopted accounting pronouncements  We have not adopted any new accounting pronouncements during the six months ended December 31, 2017 .

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Dec. 31, 2017
Inventories [Abstract]
Schedule Of Inventories	  December 31, 2017 June 30, 2017  Raw materials $ 79,246 $ 75,658  Work in progress 4,798 4,297  Finished goods 212,018 188,364  Total inventories $ 296,062 $ 268,319 

Property, Plant And Equipment (

Property, Plant And Equipment (Tables)	6 Months Ended
	Dec. 31, 2017
Property, Plant And Equipment [Abstract]
Components Of Property, Plant And Equipment	  December 31, 2017 June 30, 2017  Machinery and equipment $ 243,738 $ 230,632  Computer equipment 161,199 154,032  Furniture and fixtures 51,429 47,074  Vehicles 7,963 7,667  Clinical, demonstration and rental equipment 93,386 86,024  Leasehold improvements 37,984 35,932  Land 55,859 55,311  Buildings 236,318 233,868  887,876 850,540  Accumulated depreciation and amortization (486,339) (456,299)  Property, plant and equipment, net $ 401,537 $ 394,241 

Goodwill (Tables)

Goodwill (Tables)	6 Months Ended
	Dec. 31, 2017
Goodwill And Other Intangible Assets [Abstract]
Schedule Of Changes In Carrying Amount Of Goodwill	  Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ 1,064,874 $ 1,059,245  Business acquisition - (2,095)  Foreign currency translation adjustments 10,441 (10,846)  Balance at the end of the period $ 1,075,315 $ 1,046,304 

Other Intangible Assets (Tables

Other Intangible Assets (Tables)	6 Months Ended
	Dec. 31, 2017
Goodwill And Other Intangible Assets [Abstract]
Schedule Of Other Intangible Assets	  December 31, 2017 June 30, 2017  Developed/core product technology $ 208,445 $ 206,258  Accumulated amortization (108,715) (93,079)  Developed/core product technology, net 99,730 113,179  Trade names 48,880 48,768  Accumulated amortization (13,976) (10,894)  Trade names, net 34,904 37,874  Non-compete agreements 3,688 3,660  Accumulated amortization (2,490) (2,236)  Non-compete agreements, net 1,198 1,424  Customer relationships 123,957 122,458  Accumulated amortization (47,465) (40,050)  Customer relationships, net 76,492 82,408  In-process research and development 4,100 4,100  Accumulated amortization - -  In-process research and development, net 4,100 4,100  Patents 92,116 85,780  Accumulated amortization (68,513) (62,965)  Patents, net 23,603 22,815  Total other intangibles, net $ 240,027 $ 261,800 

Cost-Method Investments (Tables

Cost-Method Investments (Tables)	6 Months Ended
	Dec. 31, 2017
Cost-Method Investments [Abstract]
Schedule Of Reconciliation Of Changes In Cost-Method Investments	  Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ 38,324 $ 33,815  Investments 3,725 3,867  Impairment of cost-method investments (2,254) (206)  Balance at the end of the period $ 39,795 $ 37,476 

Product Warranties (Tables)

Product Warranties (Tables)	6 Months Ended
	Dec. 31, 2017
Product Warranties [Abstract]
Schedule Of Changes In Liability For Warranty Costs	  Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ 19,558 $ 15,043  Warranty accruals for the period 8,375 8,851  Warranty costs incurred for the period (7,493) (6,125)  Foreign currency translation adjustments 423 (855)  Balance at the end of the period $ 20,863 $ 16,914 

Debt (Tables)

Debt (Tables)	6 Months Ended
	Dec. 31, 2017
Debt [Abstract]
Schedule Of Debt	  December 31, 2017 June 30, 2017  Short-term debt $ 1,020,000 $ -  Deferred borrowing costs (868) -  Short-term debt, net 1,019,132 -  -  Long-term debt $ - $ 1,080,000  Deferred borrowing costs - (1,389)  Long-term debt, net $ - $ 1,078,611  Total debt $ 1,019,132 $ 1,078,611 

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	6 Months Ended
	Dec. 31, 2017
Stockholders' Equity [Abstract]
Schedule Of Option Activity	  Options Weighted Average Exercise Price Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,495,573 $ 47.09 3.9  Granted 238,815 84.98  Exercised (362,522) 33.34  Forfeited - -  Outstanding at end of period 1,371,866 $ 57.32 4.5  Exercise price of granted options $ 84.98  Options exercisable at end of period 849,755 $ 49.14 
Schedule Of Activity Of Restricted Stock Units	  Restricted Stock Units Weighted Average Grant-Date Fair Value Weighted Average Remaining Contractual Term in Years  Outstanding at beginning of period 1,906,394 $ 53.26 1.6  Granted 472,155 80.07  Vested (624,617) 52.05  Expired (8,415) 53.25  Forfeited (13,023) 53.25  Outstanding at end of period 1,732,494 $ 62.53 2.1 

Earnings Per Share (Tables)

Earnings Per Share (Tables)	6 Months Ended
	Dec. 31, 2017
Earnings Per Share [Abstract]
Schedule Of Basic And Diluted Earnings Per Share	  Three Months Ended December 31, Six Months Ended December 31,  2017 2016 2017 2016  Numerator:  Net income $ 9,527 $ 76,743 $ 95,651 $ 152,849  Denominator:  Basic weighted-average common shares outstanding 142,715 141,310 142,511 141,048  Effect of dilutive securities:  Stock options and restricted stock units 1,140 787 1,246 934  Diluted weighted average shares 143,855 142,097 143,757 141,982  Basic earnings per share $ 0.07 $ 0.54 $ 0.67 $ 1.08  Diluted earnings per share $ 0.07 $ 0.54 $ 0.67 $ 1.08 

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Dec. 31, 2017
Fair Value Measurements [Abstract]
Summary Of Financial Assets And Liabilities	  Level 1 Level 2 Level 3 Total  Balances at December 31, 2017  Foreign currency hedging instruments, net $ - $ 7,669 $ - $ 7,669  Business acquisition contingent consideration $ - $ - $ (1,580) $ (1,580)  Balances at June 30, 2017  Foreign currency hedging instruments, net $ - $ 2,760 $ - $ 2,760  Business acquisition contingent consideration $ - $ - $ (1,580) $ (1,580) 
Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs	  Six Months Ended December 31,  2017 2016  Balance at the beginning of the period $ (1,580) $ (10,450)  Changes in fair value included in operating income - (10,076)  Foreign currency translation adjustments - 19  Balance at the end of the period $ (1,580) $ (20,507) 

Legal Actions And Contingenci32

Legal Actions And Contingencies (Tables)	6 Months Ended
	Dec. 31, 2017
Legal Actions And Contingencies [Abstract]
Summary Of Receivables Sold With Recourse	  Six Months Ended December 31,  2017 2016  Total receivables sold:  Full recourse $ 9,882 $ 8,455  Limited recourse 35,960 33,794  Total 45,842 42,249 
Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision	  December 31, 2017 June 30, 2017  Maximum exposure on outstanding receivables:  Full recourse $ 18,312 $ 18,068  Limited recourse 8,687 9,432  Total 26,999 27,500   Provision for doubtful accounts - recourse receivables $ (1,279) $ (1,437) 

Derivative Instruments And He33

Derivative Instruments And Hedging Activities (Tables)	6 Months Ended
	Dec. 31, 2017
Derivative Instruments And Hedging Activities [Abstract]
Summary Of Amount And Location Of Derivative Financial Instruments	  December 31, 2017 June 30, 2017 Balance Sheet Caption  Foreign currency hedging instruments $ 9,687 $ 2,614 Other assets - current  Foreign currency hedging instruments (126) 1,273 Other assets - non current  Foreign currency hedging instruments (1,892) (1,127) Accrued expenses  $ 7,669 $ 2,760 
Summary Of Gains (Losses) Associated With Derivative Financial Instruments	  Gain /(Loss) Recognized Income Statement Caption  Six Months Ended December 31,  2017 2016  Foreign currency hedging instruments $ 1,570 $ (18,713) Other, net  Other foreign-currency-denominated transactions (2,379) 21,695 Other, net  $ (809) $ 2,982 

Summary Of Significant Accoun34

Summary Of Significant Accounting Policies (Narrative) (Details)	6 Months Ended
	Dec. 31, 2017
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Contract term under revenue recognition	1 year
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Contract term under revenue recognition	3 years

Inventories (Schedule Of Invent

Inventories (Schedule Of Inventories) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Inventories [Abstract]
Raw materials	$ 79,246	$ 75,658
Work in progress	4,798	4,297
Finished goods	212,018	188,364
Total inventories	$ 296,062	$ 268,319

Property, Plant And Equipment36

Property, Plant And Equipment (Components Of Property, Plant And Equipment) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 887,876	$ 850,540
Accumulated depreciation and amortization	(486,339)	(456,299)
Property, plant and equipment, net	401,537	394,241
Machinery And Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	243,738	230,632
Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	161,199	154,032
Furniture And Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	51,429	47,074
Vehicles [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	7,963	7,667
Clinical, Demonstration And Rental Equipment [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	93,386	86,024
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	37,984	35,932
Land [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	55,859	55,311
Buildings [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 236,318	$ 233,868

Goodwill (Schedule Of Changes I

Goodwill (Schedule Of Changes In Carrying Amount Of Goodwill) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Goodwill And Other Intangible Assets [Abstract]
Balance at the beginning of the period	$ 1,064,874	$ 1,059,245
Business acquisition		(2,095)
Foreign currency translation adjustments	10,441	(10,846)
Balance at the end of the period	$ 1,075,315	$ 1,046,304

Other Intangible Assets (Schedu

Other Intangible Assets (Schedule Of Other Intangible Assets) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Finite-Lived Intangible Assets [Line Items]
Total other intangibles, net	$ 240,027	$ 261,800
Developed/Core Product Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	208,445	206,258
Accumulated amortization	(108,715)	(93,079)
Total other intangibles, net	99,730	113,179
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	48,880	48,768
Accumulated amortization	(13,976)	(10,894)
Total other intangibles, net	34,904	37,874
Non-Compete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	3,688	3,660
Accumulated amortization	(2,490)	(2,236)
Total other intangibles, net	1,198	1,424
Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	123,957	122,458
Accumulated amortization	(47,465)	(40,050)
Total other intangibles, net	76,492	82,408
In-Process Research And Development [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	4,100	4,100
Total other intangibles, net	4,100	4,100
Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Other intangibles, gross	92,116	85,780
Accumulated amortization	(68,513)	(62,965)
Total other intangibles, net	$ 23,603	$ 22,815
Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	2 years
Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Intangible assets, estimated useful life	15 years

Cost-Method Investments (Narrat

Cost-Method Investments (Narrative) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2016
Cost-Method Investments [Abstract]
Aggregate carrying amount of cost-method investments	$ 39,795	$ 37,476	$ 38,324	$ 33,815
Impairment losses related to cost-method investments	$ 2,254	$ 206

Cost-Method Investments (Schedu

Cost-Method Investments (Schedule Of Reconciliation Of Changes In Cost-Method Investments) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Cost-Method Investments [Abstract]
Balance at the beginning of the period	$ 38,324	$ 33,815
Investments	3,725	3,867
Impairment of cost-method investments	(2,254)	(206)
Balance at the end of the period	$ 39,795	$ 37,476

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Thousands	Dec. 22, 2017	Dec. 31, 2017	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Income Taxes [Line Items]
Income tax expense (benefit)			$ 132,238	$ 19,464	$ 154,599	$ 36,282
Tax Year 2018 [Member]
Income Taxes [Line Items]
Income tax expense (benefit)	$ 126,600
Additional income tax expense from transition tax imposed on accumulated foreign earnings	119,900
Additional income tax expense from adjustment of deferred tax assets	$ 6,700
Australian Taxation Office [Member]
Income Taxes [Line Items]
Total additional tax liabilities related to audit		$ 150,000
Australian Taxation Office [Member] | Minimum [Member]
Income Taxes [Line Items]
Tax year under audit					2,009
Australian Taxation Office [Member] | Maximum [Member]
Income Taxes [Line Items]
Tax year under audit					2,013

Product Warranties (Schedule Of

Product Warranties (Schedule Of Changes In Liability For Warranty Costs) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Product Warranties [Abstract]
Balance at the beginning of the period	$ 19,558	$ 15,043
Warranty accruals for the period	8,375	8,851
Warranty costs incurred for the period	(7,493)	(6,125)
Foreign currency translation adjustments	423	(855)
Balance at the end of the period	$ 20,863	$ 16,914

Debt (Narrative) (Details)

Debt (Narrative) (Details) - USD ($) $ in Thousands	Jan. 09, 2017	Apr. 04, 2016	Oct. 31, 2013	Dec. 31, 2017	Jan. 08, 2017	Apr. 03, 2016
Debt Instrument [Line Items]
Outstanding under the revolving credit facility				$ 1,019,132
Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity	$ 1,300,000		$ 700,000		$ 1,000,000	$ 700,000
Uncommitted option to increase credit facility	$ 300,000		$ 300,000
Credit facility termination date				Oct. 31, 2018
Interest rate on outstanding principal amount				2.80%
Union Bank, N.A. and HSBC Bank USA [Member] | Letters Of Credit [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity				$ 25,000
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility				0.15%
Minimum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus				1.00%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member]
Debt Instrument [Line Items]
Commitment fees percentage rate on unused portion of credit facility				0.25%
Maximum [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Credit facility interest rate equal to reference rate plus				2.00%
Brightree LLC [Member] | Union Bank, N.A. and HSBC Bank USA [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Maximum borrowing capacity		$ 1,000,000
Uncommitted option to increase credit facility		$ 300,000

Debt (Schedule Of Debt) (Detail

Debt (Schedule Of Debt) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Debt [Abstract]
Short-term debt	$ 1,020,000
Deferred borrowing costs	(868)
Short-term debt, net	1,019,132
Long-term debt		$ 1,080,000
Deferred borrowing costs		(1,389)
Long-term debt, net		1,078,611
Total debt	$ 1,019,132	$ 1,078,611

Stockholders' Equity (Narrative

Stockholders' Equity (Narrative) (Details) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended		6 Months Ended
	Dec. 31, 2017	Nov. 30, 2017	Dec. 31, 2017	Dec. 31, 2016	Jun. 30, 2017	Apr. 30, 1997
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common shares repurchased under repurchase program			100,000
Cost of common shares repurchased			$ 8,500
Total number of shares repurchased pursuant to the repurchase program	41,186,234		41,186,234		41,086,234
Total cost of shares repurchased pursuant to the repurchase program	$ 1,555,152		$ 1,555,152		$ 1,546,611
Additional shares that can be repurchased under the approved share repurchase program	13,500,000		13,500,000
Preferred stock, shares authorized	2,000,000		2,000,000		2,000,000
Preferred stock at par value	$ 0.01		$ 0.01		$ 0.01
Preferred stock, shares issued	0		0		0
Series A Junior Participating Preferred Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Preferred stock, shares authorized						2,000,000
Preferred stock at par value						$ 0.01
Preferred stock, shares issued	0		0		0
Preferred stock, shares outstanding	0		0		0
2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expiration period			7 years
Maximum amount payable pursant to cash denominated performance awards granted	$ 5,000	$ 3,000
Vesting period		4 years
Expiration date		Sep. 11, 2027
Common stock authorized for issuance	51,100,000		51,100,000
Common stock authorized for issuance and pending registration		7,400,000
Number of securities remaining available for future issuance	17,600,000		17,600,000
2009 Plan [Member] | Non Employee Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum award amount with other cash fees earned for services		$ 700
2009 Plan [Member] | Board Of Directors Chairman [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum award amount with other cash fees earned for services		$ 1,200
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of securities remaining available for future issuance	700,000		700,000
Shares issued under Employee Stock Purchase Plan			148,000	142,000
Minimum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			1 year
Maximum [Member] | 2009 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			4 years

Stockholders' Equity (Schedule

Stockholders' Equity (Schedule Of Option Activity) (Details) - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Stockholders' Equity [Abstract]
Options, Outstanding at beginning of period	1,495,573
Options, Granted	238,815
Options, Exercised	(362,522)
Options, Forfeited
Options, Outstanding at end of period	1,371,866	1,495,573
Options, Exercise price of granted options	$ 84.98
Options exercisable at end of period	849,755
Weighted Average Exercise Price, Outstanding at beginning of period	$ 47.09
Weighted Average Exercise Price, Granted	84.98
Weighted Average Exercise Price, Exercised	33.34
Weighted Average Exercise Price, Forfeited
Weighted Average Exercise Price, Outstanding at end of period	57.32	$ 47.09
Weighted Average Exercise Price, Options exercisable at end of period	$ 49.14
Weighted Average Remaining Contractual Term in Years, Outstanding	4 years 6 months	3 years 10 months 24 days

Stockholders' Equity (Schedul47

Stockholders' Equity (Schedule Of Activity Of Restricted Stock Units) (Details) - Restricted Stock Units (RSUs) [Member] - $ / shares	6 Months Ended	12 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restricted Stock Units, Outstanding at beginning of period	1,906,394
Restricted Stock Units, Granted	472,155
Restricted Stock Units, Vested	(624,617)
Restricted Stock Units, Expired	(8,415)
Restricted Stock Units, Forfeited	(13,023)
Restricted Stock Units, Outstanding at end of period	1,732,494	1,906,394
Weighted Average Grant-Date Fair Value, Outstanding at beginning of period	$ 53.26
Weighted Average Grant-Date Fair Value, Granted	80.07
Weighted Average Grant-Date Fair Value, Vested	52.05
Weighted Average Grant-Date Fair Value, Expired	53.25
Weighted Average Grant-Date Fair Value, Forfeited	53.25
Weighted Average Grant-Date Fair Value, Outstanding at end of period	$ 62.53	$ 53.26
Weighted Average Remaining Contractual Term in Years, Outstanding	2 years 1 month 6 days	1 year 7 months 6 days

Earnings Per Share (Narrative)

Earnings Per Share (Narrative) (Details) - shares	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Earnings Per Share [Abstract]
Stock options and restricted stock units not included in the computation of diluted earnings per share	126,390	410,520	159,603	337,487

Earnings Per Share (Schedule Of

Earnings Per Share (Schedule Of Basic And Diluted Earnings Per Share) (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2017	Dec. 31, 2016
Numerator:
Net income	$ 9,527	$ 76,743	$ 95,651	$ 152,849
Denominator:
Basic weighted-average common shares outstanding	142,715	141,310	142,511	141,048
Effect of dilutive securities:
Stock options and restricted stock units	1,140	787	1,246	934
Diluted weighted average shares	143,855	142,097	143,757	141,982
Basic earnings per share	$ 0.07	$ 0.54	$ 0.67	$ 1.08
Diluted earnings per share	$ 0.07	$ 0.54	$ 0.67	$ 1.08

Fair Value Measurements (Summar

Fair Value Measurements (Summary Of Financial Assets And Liabilities) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	$ 7,669	$ 2,760
Business acquisition contingent consideration	(1,580)	(1,580)
Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration
Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net	7,669	2,760
Business acquisition contingent consideration
Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency hedging instruments, net
Business acquisition contingent consideration	$ (1,580)	$ (1,580)

Fair Value Measurements (Reconc

Fair Value Measurements (Reconciliation For Fair Value Measurements Using Significant Unobservable Inputs) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Fair Value Measurements [Abstract]
Balance at the beginning of the period	$ (1,580)	$ (10,450)
Changes in fair value included in operating income		(10,076)
Foreign currency translation adjustments		19
Balance at the end of the period	$ (1,580)	$ (20,507)

Legal Actions And Contingenci52

Legal Actions And Contingencies (Summary Of Receivables Sold With Recourse) (Details) - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Contingent Obligations Under Recourse Provisions [Line Items]
Total receivables sold	$ 45,842	$ 42,249
Full Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Total receivables sold	9,882	8,455
Limited Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Total receivables sold	$ 35,960	$ 33,794

Legal Actions And Contingenci53

Legal Actions And Contingencies (Summary Of Maximum Exposure On Outstanding Receivables Sold With Recourse And Provision) (Details) - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Contingent Obligations Under Recourse Provisions [Line Items]
Maximum exposure on outstanding receivables	$ 26,999	$ 27,500
Provision for doubtful accounts - recourse receivables	(1,279)	(1,437)
Full Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Maximum exposure on outstanding receivables	18,312	18,068
Limited Recourse [Member]
Contingent Obligations Under Recourse Provisions [Line Items]
Maximum exposure on outstanding receivables	$ 8,687	$ 9,432

Derivative Instruments And He54

Derivative Instruments And Hedging Activities (Narrative) (Details) - USD ($) $ in Millions	6 Months Ended
	Dec. 31, 2017	Jun. 30, 2017
Derivative [Line Items]
Notional amount of foreign currency hedging contracts held	$ 789.3	$ 568.2
Foreign Currency Hedging Instruments [Member]
Derivative [Line Items]
Terms of foreign currency hedging contracts, maximum	3 years
Maturity date	Dec. 31, 2019

Derivative Instruments And He55

Derivative Instruments And Hedging Activities (Summary Of Amount And Location Of Derivative Financial Instruments) (Details) - Foreign Currency Hedging Instruments [Member] - USD ($) $ in Thousands	Dec. 31, 2017	Jun. 30, 2017
Derivatives, Fair Value [Line Items]
Net foreign currency hedging instruments	$ 7,669	$ 2,760
Other Assets - Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets	9,687	2,614
Other Assets - Non Current [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, assets		1,273
Foreign currency hedging instruments, liabilities	(126)
Accrued Expenses [Member]
Derivatives, Fair Value [Line Items]
Foreign currency hedging instruments, liabilities	$ (1,892)	$ (1,127)

Derivative Instruments And He56

Derivative Instruments And Hedging Activities (Summary Of Gains (Losses) Associated With Derivative Financial Instruments) (Details) - Derivatives Not Designated As Hedging Instruments [Member] - USD ($) $ in Thousands	6 Months Ended
	Dec. 31, 2017	Dec. 31, 2016
Derivative Instruments, Gain (Loss) [Line Items]
Gain (loss) recognized in income	$ (809)	$ 2,982
Foreign Currency Hedging Instruments [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign currency hedging instruments	1,570	(18,713)
Other Foreign-Currency-Denominated Transactions [Member] | Other, Net [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Other foreign-currency-denominated transactions	$ (2,379)	$ 21,695